Bio-Techne Corporation and Spear Bio Announce Strategic Partnership to Advance Therapeutic Development with Ultras sensitive Biomarker Detection

Published: 2025-07-15 11:51:22 ET TECH

Published on 07/15/2025 at 11:51

Bio-Techne Corporation announced a strategic partnership to distribute Spear Bio's next-generation ultrasensitive immunoassays, enabling the detection of low-abundance biomarkers in neurology. Under the agreement, Bio-Techne will distribute Spear Bio's ultrasensitive immunoassays for challenging low-abundance biomarker detection, including key Alzheimer's disease biomarkers such as phosphorylated tau 217 (pTau 217), GFAP, neurofilament light (Nf-L), and phosphorylated tau231 (pTau 231). The initial offering will focus on key biomarkers supporting translational research in Alzheimer's disease.

This partnership follows Bio-Techne's participation in Spear Bio's $45 million Series A funding round in 2024. Early detection of protein biomarkers is essential for understanding historically challenging disease mechanisms, developing early interventions, and advancing clinical trials. Spear Bio's Successive Proximity Extension Amplification Reaction (SPEAR) platform, based on breakthrough technology licensed from Harvard University, and amplified using conventional qPCR instrumentation, offers sensitivity two to three orders of magnitude higher than current immunoassay platforms. With Bio-Techne's global reach, Spear Bio is well-positioned to accelerate the deployment of its next-generation assay technology, enabling researchers to detect biomarkers in historically challenging conditions.

Spear Bio's initial focus is neurodegenerative diseases, with the technology relevant for inflammation, oncology and additional fields. In addition, Spear Bio's advanced detection technology expands applications in high-growth markets, including early neurodegenerative disease diagnosis, enhancing patient access to critical interventions. This partnership underscores the promise of Spear Bio's SPEAR technology and reinforces Bio-Techne's commitment to advancing biomarker detection.